Novo Nordisk Update | NVO
One of our long ideas is Novo Nordisk. The company had an earings announcement on May 6, and we thought this would be an opportune time to revisit the company.…
Novo Nordisk Update | NVO
On December 22, 2025, the FDA approved Novo Nordisk's once-daily oral semaglutide (branded as the Wegovy pill), marking the first oral GLP-1 receptor agonist specifically for chronic weight management in…
Novo Nordisk Update | NVO
Novo Nordisk is an ethical drug development company operating out of Denmark. It is a company we think will perform well, with an undervalued stock. This article is for paid…
Novo Nordisk: NVO
On March 31, 2025, we suggested traders take a bullish position in NVO by selling a cash-covered put option on the stock. This article is for paid members - please…
Novo Nordisk: NVO
Diabetes is a chronic illness that seems to keep getting worse. Some people are born with it. However, we think the primary cause is diet. In particular, we point to…
Novo Nordisk: NVO
The ethical drug company Novo Nordisk will report earnings on Wednesday, January 31. Analysts expect the company to report EPS of $0.67 on revenue of $8.7 billion. This article is…